POS1240 HIGH PREVALENCE OF SERUM AUTOANTIBODIES IN SEVERELY ILL COVID-19 PATIENTS HOSPITALIZED IN THE INTENSIVE CARE UNIT.
Authors: K. Bitzogli, E. Jahaj, A. D. Bakasis, E. Kapsogeorgou, A. Goules, I. Stergiou, V. Pezoulas, P. Skendros, K. Ritis, D. I. Fotiadis, A. Kotanidou, A. Tzioufas, P. Vlachoyiannopoulos
Journal: Annals of the Rheumatic Diseases (2022)

Background Coronavirus Disease-19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is characterized by a wide range of clinical manifestations 1 . Although COVID-19 was initially considered a respiratory infection, it was shortly recognized as a multisystemic disorder associated with heightened inflammatory responses, including autoimmune phenomena 1 . The presence of autoantibodies (AAbs) has been described in COVID-19 patients, highlighting the state of immune dysregulation in COVID-19 1 . The clinical significance of AAbs, however, is still elusive. Objectives To assess the prevalence of AAbs in critically ill, mechanically ventilated COVID-19 patients admitted to the intensive care unit (ICU) and investigate whether AAbs influence the clinical outcome of these patients. Methods The current study evaluated prospectively from March 8th, 2021 to May 10th, 2021 the presence of AAbs against nuclear antigens (ANA), extractable nuclear antigens (ENA), neutrophil cytoplasmic antigens (ANCA), cyclic citrullinated peptides (anti-CCP), double stranded-DNA (anti-dsDNA), cardiolipin (anti-CL), β2-glycoprotein-I (anti-β2-GPI), thyroid peroxidase (anti-TPO), and thyroglobulin (anti-TG) in critically ill COVID-19 patients upon admission in the ICU (n=217). Samples from 60 COVID-19 patients that were available 15 days after ICU admission were further analyzed for the evaluation of de novo AAbs production. Serum samples of age and sex matched healthy individuals before the COVID-19 pandemic were used as a control group (n=117). Results COVID-19 patients treated in ICU had more commonly at least one AAb compared to age and sex matched controls (174/217, 80.2% vs 73/217, 62,4%, p&lt; 0,001). More specifically, COVID-19 patients expressed more frequently ANAs (48.4% vs 21.4%, p&lt;0.001), anti-dsDNA (5.1% vs 0%, p=0.01), anti-CCP (8.3% vs 1.7%, p=0.014) and anti-CL IgM AAbs (21.7% vs 9.4%, p=0.005) than controls. The majority of critical COVID-19 patients who were positive for AAbs (144, 82.8%) expressed reactivity in up to three autoantigens with the most prominent being ANA, anti-phospholipid, ANCA and anti-TPO AAbs. AAbs-positive patients demonstrated more robust anti-SARS-CoV-2 humoral responses compared to AAbs-negative patients [detectable anti-SARS-CoV-2 S1-protein IgG antibodies: 150 (86.2%) vs 28 (65.1%), p=0.001; adequate neutralizing activity: 159 (91.4%) vs. 33 (76.7%), p=0.007]. The two groups, however, did not differ in terms of clinicoepidemiologic characteristics or the incidence of death in the ICU. Convalescent COVID-19 patients (n=111) compared to those who died (n=106), did not differ in the prevalence of serum AAbs or antibody responses against SARS-CoV-2. Differences were only shown in clinicolaboratory parameters including patients’ age, comorbidities, O2 saturation, inflammatory markers, and in-hospital prognostic scores as expected. Paired samples testing (n=60) revealed that 45 patients had at least one newly induced AAb, 28 patients lost at least one reactivity and only 6 patients didn’t show any seroconversion. The most common new-onset AAb reactivity was against anti-CL (IgG isotype) (n=21) followed by ANA (n=20), anti-β2-GPI (IgG isotype) (n=11), myositis-related antigens (n=13) and ENAs (n=9); nevertheless, no associations with clinicoepidemiologic features or COVID-19 outcome were revealed. Conclusion Patients with severe COVID-19 express AAbs more commonly than age and sex matched controls, suggesting that SARS-COV-2 infection may induce a hitherto unknown B-cell autoreactivity. The presence of autoantibodies does not play a role in the outcome of SARS-COV-2 infection. However, further studies are needed to define their role in future development of systemic autoimmune disorders or the long-COVID syndrome. References [1]Kaklamanos, A.; et al. COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Front Immunol 2021, 12, 719023, doi:10.3389/fimmu.2021.719023. Acknowledgements The experimental arm of the current study was financially supported by donation grants from SYN-ENOSIS (Greece) Disclosure of Interests None declared